Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5196498
Max Phase: Preclinical
Molecular Formula: C43H41F3N10O8
Molecular Weight: 882.86
Associated Items:
ID: ALA5196498
Max Phase: Preclinical
Molecular Formula: C43H41F3N10O8
Molecular Weight: 882.86
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(=O)CCCC(=O)Nc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1
Standard InChI: InChI=1S/C43H41F3N10O8/c1-3-33(57)48-24-7-4-8-25(21-24)49-38-28(43(44,45)46)23-47-42(53-38)51-29-14-13-26(22-32(29)64-2)54-17-19-55(20-18-54)36(60)12-6-11-34(58)50-30-10-5-9-27-37(30)41(63)56(40(27)62)31-15-16-35(59)52-39(31)61/h3-5,7-10,13-14,21-23,31H,1,6,11-12,15-20H2,2H3,(H,48,57)(H,50,58)(H,52,59,61)(H2,47,49,51,53)
Standard InChI Key: OBHMXNAEXVRWTQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 882.86 | Molecular Weight (Monoisotopic): 882.3061 | AlogP: 4.97 | #Rotatable Bonds: 14 |
Polar Surface Area: 224.37 | Molecular Species: NEUTRAL | HBA: 13 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.57 | CX Basic pKa: 4.34 | CX LogP: 4.50 | CX LogD: 4.50 |
Aromatic Rings: 4 | Heavy Atoms: 64 | QED Weighted: 0.08 | Np Likeness Score: -1.12 |
1. Li Q, Guo Q, Wang S, Wan S, Li Z, Zhang J, Wu X.. (2022) Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686., 238 [PMID:35594654] [10.1016/j.ejmech.2022.114455] |
Source(1):